As the number of antimicrobial-resistant infections worldwide is growing exponentially, the need for feasible and effective alternatives to antibiotics has skyrocketed. Drug developers are combating antibiotic resistance by translating bacteriophages into robust clinical candidates and are navigating the regulatory challenges with GMP manufacturing.
The 7th Bacteriophage Therapy Summit will unite industry leaders, such as Armata Pharmaceuticals, Phiogen Pharma, and TechnoPhage as they share clinical data, dive into the investment opportunities for bacteriophage companies, and tackle the regulatory challenges in development.
Top 5 Reasons to Attend:
Target bacterial infections rapidly with personalized and off-the-shelf bacteriophages with wide coverage of strains with Kinzbio, Cytophage and PhagePro
Supercharge the investment opportunities for bacteriophage companies to proceed to the clinic and prove viability as an alternative to antibiotics with BARDA, Sozo Ventures, and Phiogen Pharma
Discover the most recent updates from pivotal phase II clinical trials with Armata Pharmaceuticals as they move beyond compassionate use of bacteriophages to fight AMR bacteria
Accomplish market approval for bacteriophage therapies by diving into the current regulatory guidelines with TechnoPhage and Precisio Biotix Therapeutics
Achieve sustainable commercialization of bacteriophages post-approval, with a reimbursement strategy with Cytophage and PhagePro
